Skip to main content
. 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334

Figure 7.

Figure 7

Flowchart describing the proportion of referred R/R LBCL patients with the appropriate indication as per the product registration label who benefit from axicabtagene ciloleucel. Abbreviations: Axi-cel: axicabtagene ciloleucel, LBCL: large B-cell lymphoma, R/R: relapsed/refractory.